New spinal fluid treatment targets deadly cancer spread
NCT ID NCT06462222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for leptomeningeal metastasis, a condition where cancer spreads to the lining of the brain and spinal cord. The treatment combines an immune checkpoint inhibitor (a drug that helps the immune system fight cancer) with pemetrexed (a chemotherapy drug), both injected directly into the spinal fluid. The study involves 45 adults with solid tumors and aims to find the safest dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Chest Hospital, Capital Medical University
Beijing, 101100, China
-
Cancer Center, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
Beijing, China
-
Huizhou First Hospital Affiliated to Guangdong Medical University
Huizhou, Guangdong, China
-
The Affiliated Huizhou Hospital, Guangzhou Medical University
Huizhou, Guangdong, 516000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Spinal fluid injection of Dual-Target antibody and chemotherapy shows promise for deadly cancer complication
- Smartwatch could alert doctors to brain cancer complications before they worsen
- Triple therapy targets tough brain metastases in lung cancer
- New hope for lung cancer patients with brain-spread disease
- New hope for lung cancer patients with brain spread: targeted pill under study